Here are the 10-Q quarterly reports from Drugs Made In America Acquisition II Corp. Right (DMIIR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DMIIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMIIR filings page.
Drugs Made In America Acquisition II Corp., a Cayman Islands blank check company, reports interim results as it seeks a pharmaceutical-focused business combination. It completed a $500,000,000 IPO in September 2025 and held $513,882,333 in a U.S. Treasury–invested Trust Account as of June 30, 2026, corresponding to 50,000,000 redeemable ordinary shares.
For the six months ended June 30, 2026, the company generated net income of $8,734,276, driven primarily by $8,948,533 of interest on Trust investments, while incurring $244,257 of general and administrative costs. Operating liquidity remains tight, with cash of $174,974, a working capital deficit of $426,751, and $17,500,000 of deferred underwriting fees plus $450,000 of convertible promissory notes outstanding. Management discloses substantial doubt about the company’s ability to continue as a going concern if no business combination occurs within the 24‑month combination period and also reports material weaknesses in internal controls, including inadequate segregation of duties and insufficient policies around related‑party approvals.
Drugs Made in America Acquisition II Corp. reported Q1 2026 net income of $4.34M, driven almost entirely by $4.44M of interest earned on $509.37M of cash and investments held in its SPAC trust account, while general and administrative costs were $132K.
Operating cash remains limited with $347,720 of cash and a working capital deficit of about $315K as of March 31, 2026, and management cites substantial doubt about its ability to continue as a going concern without completing a business combination within the 24‑month Combination Period. The company fully reserved $782,113 due from its sponsor and raised $450K via convertible notes that can convert at a 35% discount upon a future business combination.